CXCR6: A protein at the center of drug development (G10663)

Target Name: CXCR6

NCBI ID: G10663

CXCR6

CXCR6: A protein at the center of drug development

CXCR6, also known as BONZO, is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is a member of the bone marrow-derived cell surface glycoprotein family, which includes proteins such as CD33, GlyCAM, and Mucin 1 (MUC1).

CXCR6 is involved in several cellular processes that are critical for normal tissue growth, development, and function. It is a key regulator of cell adhesion, migration, and angiogenesis, which are all essential processes that play a critical role in the development and maintenance of tissues.

CXCR6 is also involved in the regulation of inflammation and immune responses. It has been shown to play a critical role in the regulation of T cell development and function, as well as the regulation of granulocyte responses to infection.

Given its involvement in so many critical cellular processes, CXCR6 has been identified as a potential drug target. Researchers are currently working to develop small molecules that can inhibit the activity of CXCR6, with the goal of using these drugs to treat a variety of diseases.

One of the challenges in developing drugs that target CXCR6 is its complex biology. CXCR6 is expressed in a wide variety of tissues and cells, and it is involved in the regulation of many different cellular processes. This makes it difficult to identify small molecules that can effectively inhibit its activity.

In addition, CXCR6 is highly expressed in many diseases, including cancer, which can make it difficult to develop drugs that are specific enough to target this protein without causing unintended side effects.

Despite these challenges, researchers are making progress in the development of drugs that target CXCR6. One of the most promising approaches is the use of small molecules that can inhibit the activity of CXCR6 by blocking its interaction with other proteins.

In addition to its potential as a drug target, CXCR6 is also being investigated as a biomarker for several diseases. Its expression has been shown to be elevated in a variety of diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.

By studying the expression and activity of CXCR6, researchers hope to develop new diagnostic tests and therapies that can be used to treat these diseases.

Overall, CXCR6 is a protein that is involved in many critical cellular processes that are essential for normal tissue growth and development. Its potential as a drug target and biomarker make it an attractive target for researchers to investigate further. As research continues, we can expect to learn more about the role of CXCR6 in disease and to develop new treatments that can help to improve the health and well-being of many people.

Protein Name: C-X-C Motif Chemokine Receptor 6

Functions: Receptor for the C-X-C chemokine CXCL16. Used as a coreceptor by SIVs and by strains of HIV-2 and m-tropic HIV-1

The "CXCR6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CXCR6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets